Aileron Therapeutics Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park CapitalGlobeNewsWire • 09/21/20
Aileron Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 08/05/20
Aileron Therapeutics to Present at Two Upcoming Investor Conferences in AugustGlobeNewsWire • 08/03/20
Aileron Therapeutics Announces Completion of Enrollment in Dose Optimization Expansion Cohort of Proof-of-Concept Phase 1b Study of ALRN-6924GlobeNewsWire • 08/03/20
Aileron Therapeutics Initiates Enrollment in Schedule Optimization Part of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent in Small Cell Lung Cancer (SCLC) Patients Being Treated with TopotecanGlobeNewsWire • 06/29/20
Aileron Therapeutics Announces Closing of Public Offering of Common Stock and Exercise of Option to Purchase Additional SharesGlobeNewsWire • 06/10/20
Aileron Therapeutics Announces Initiation of Expansion Cohort and First Patient Enrolled into Expansion Cohort of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection AgentGlobeNewsWire • 05/27/20
Aileron Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/11/20
Aileron Therapeutics Announces Plans to Release Interim Results from its Phase 1b/2 Myelopreservation Study in Mid-2020GlobeNewsWire • 04/22/20
Aileron Therapeutics Announces the Promotion of Richard J. Wanstall to Chief Financial Officer and TreasurerGlobeNewsWire • 12/18/19
Aileron Therapeutics, Inc. (ALRN) CEO Manuel Aivado on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/10/19
Aileron Therapeutics Announces Positive Nonclinical Myelopreservation Results for ALRN-6924 at the 2019 AACR-NCI-EORTC ConferenceGlobeNewsWire • 10/29/19
Aileron to Present Nonclinical Myelopreservation Data for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference on October 29thGlobeNewsWire • 10/21/19
Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation AgentGlobeNewsWire • 10/16/19
Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer’s Palbociclib at the 2019 Congress of the European Society for Medical OncologyGlobeNewsWire • 09/28/19
Aileron to Present Interim Phase 2a Clinical Data for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers at the 2019 Congress of the European Society for Medical OncologyGlobeNewsWire • 09/24/19
Aileron Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference in New YorkGlobeNewsWire • 09/03/19